ModernGraham Valuation

Company Name:

Chemed Corporation



5.19 Fail

Company Ticker Date of Analysis

12/14/2016

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

7. Moderate Price to Assets

 Adequate Size of the Enterprise 	Market Cap > \$2Bil	\$2,494,221,889 Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	0.79 Fail
3. Earnings Stability	Positive EPS for 10 years prior	Pass
4. Dividend Record	Dividend Payments for 10 years prior	Pass
5. Earnings Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	113.73% Pass
J. Lannings Growth	beginning and end	113.7370 1 833
Moderate PEmg Ratio	PEmg < 20	25.97 Fail

PB Ratio < 2.5 OR PB*PEmg < 50

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	0.79 Fail
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	-2.97 Fail
3. Earnings Stability	Positive EPS for 5 years prior	Pass
Dividend Record	Currently Pays Dividend	Pass
5. Earnings Growth	EPSmg greater than 5 years ago	Pass

Suitability

Defensive No Enterprising No

Stage 2: Determination of Intrinsic Value

EPSmg	\$5.87
MG Growth Estimate	7.21%
MG Value	\$134.66
MG Value based on 3% Growth	\$85.18
MG Value based on 0% Growth	\$49.93
Market Implied Growth Rate	8.74%

MG Opinion

Current Price \$152.59 % of Intrinsic Value 113.31%

Opinion Overvalued

MG Grade D

Stage 3: Information for Further Research

Growth

Net Current Asset Value (NCAV)	-\$13.43
Graham Number	\$66.94
PEmg	25.97
Current Ratio	0.79
PB Ratio	5.19
Current Dividend	\$0.98
Dividend Yield	0.64%
Number of Consecutive Years of Dividend	

 Useful Links:
 ModernGraham tagged articles
 Morningstar


 Google Finance
 MSN Money

 Yahoo Finance
 Seeking Alpha

 GuruFocus
 SEC Fillings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate	*****	Next Fiscal Year Estimate	\$5.87
Dec2015	\$6.33	Dec2015	\$5.32
Dec2014	\$5.57	Dec2014	\$4.67
Dec2013	\$4.16	Dec2013	\$4.13
Dec2012	\$4.62	Dec2012	\$3.97
Dec2011	\$4.10	Dec2011	\$3.52
Dec2010	\$3.55	Dec2010	\$3.09
Dec2009	\$3.24	Dec2009	\$2.70
Dec2008	\$2.88	Dec2008	\$2.28
Dec2007	\$2.55	Dec2007	\$1.77
Dec2006	\$1.90	Dec2006	\$1.19
Dec2005	\$1.36	Dec2005	\$0.66
Dec2004	\$1.12	Dec2004	\$0.28
Dec2003	-\$0.18	Dec2003	-\$0.02
Dec2002	-\$0.13	Dec2002	\$0.18
Dec2001	-\$0.63	Dec2001	\$0.48
Dec2000	\$1.01	Dec2000	\$1.09
Dec1999	\$0.93	Balance Sheet Information	9/1/2016
Dec1998	\$0.99	Total Current Assets	\$132,959,000
Dec1997	\$1.51	Total Current Liabilities	\$167,457,000
Dec1996	\$1.63	Long-Term Debt	\$102,500,000
		Total Assets	\$842,476,000
		Intangible Assets	\$527,485,000
		Total Liabilities	\$355,274,000
		Shares Outstanding (Diluted Average)	16,559,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company #N/A

Other ModernGraham posts about related companies <u>Surgical Care Affiliates Inc Valuation – Initial Coverage \$SCAI</u>

<u>Thermo Fisher Scientific Inc Valuation – December 2016 \$TMO</u>

Illumina Inc Valuation – Initial Coverage \$ILMN

Thermo Fisher Scientific Inc Valuation – November 2016 \$TMO

Waters Corporation Valuation - November 2016 \$WAT

Align Technology Inc Valuation - August 2016 \$ALGN

HCA Holdings Inc Valuation – August 2016 \$HCA

Express Scripts Holding Co Valuation - August 2016 \$ESRX

Universal Health Services Inc Valuation – August 2016 \$UHS

Endo International PLC Valuation - August 2016 \$ENDP